Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047502 · ClinicalTrials.gov registry record · Phase 1
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00047502: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00047502 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047502, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study if to investigate the effect of lonafarnib (SCH66336) in combination with Gleevec in the treatment of CML.
Interventions
- DRUG Lonafarnib (SCH66336)
- DRUG Imatinib Mesylate (Gleevec)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2002-11-01 |
| Est. Completion | 2006-04-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047502
The ClinicalTrials.gov registry entry for NCT00047502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lonafarnib (SCH66336) is the first listed.
NCT00047502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00047502 about?
NCT00047502 is a clinical study titled "Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia". The purpose of this study if to investigate the effect of lonafarnib (SCH66336) in combination with Gleevec in the treatment of CML.
What is the current status of trial NCT00047502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2002-11-01. Estimated completion is 2006-04-10.
What interventions are being tested in trial NCT00047502?
The interventions under investigation include: Lonafarnib (SCH66336) (DRUG), Imatinib Mesylate (Gleevec) (DRUG).
Who is sponsoring clinical trial NCT00047502?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.